|
From: trigonometry1972 on 30 Apr 2008 03:15 On Apr 24, 7:05 pm, Bruce in Bangkok <b*paige*125@g*mail.com> wrote: > On Thu, 24 Apr 2008 20:33:27 -0400, Larry <la...(a)nospam.net> wrote: > >A complete clinical trial result lists the side effects and the > >percentage of patients affected by each ... along with the number of > >patients tested. I don't see that here. Can you point me to that > >information because that's what I was looking for. Thanks. > > >Larry > > >BoneLady wrote: > >> On Apr 23, 4:58 pm, Larry <la...(a)nospam.net> wrote: > > >>>BoneLady wrote: > > >>>>Are you interested in an alternative to prescription drugs for > >>>>osteoporosis? athttp://strontiumforbones.blogspot.com/. My > > >>>>>Can I just ask ... since this is not a prescription that is dispensed by > > >>>a pharmacy and prescribed by a doctor, and has never been through any > >>>kind of clinical trial, how would we really know whether there are side > >>>effects or not? > > >>>Larry > > The Strontium ranelate I take (a prescription medicine, by the way) > comes complete with the standard physician's information sheet listing > dosages, side effects, results of testing, and so on. It appears to > be a professionally produced product (Les Laboratoire Servier - > France). > > Bruce-in-Bangkok > (correct email address for reply) No, I think you misunderstand Larry. He is casting his doubts on strontium citrate not on strontium ranelate. No matter as Bonelady points out whichever salt it is contained in here is going to disassociate in the stomach and intestines. Trig "The world has too few chemistry majors and too many lawyers. There is too much bad common sense and too little good sense and the latter is rarely common........Trig"
From: Ron Peterson on 30 Apr 2008 17:44 On Apr 24, 2:43 pm, BoneLady <srsuppor...(a)gmail.com> wrote: > On Apr 23, 6:12 pm, Ron Peterson <r...(a)shell.core.com> wrote: > > I don't believe that strontium is considered a nutrient and that makes > > it difficult to recommend. > Strontium is considered to be an essential nutrient like calcium and > is available in small amounts from food. It is believed that the > strontium-calcium bone matrix is far stronger than calcium matrix > alone. Who considers strontium to be an essential nutrient? Is there a study that indicates that strontium in the bone matrix is the cause of higher bone strength? -- Ron
From: Bruce in Bangkok on 30 Apr 2008 20:26 On Wed, 30 Apr 2008 14:44:21 -0700 (PDT), Ron Peterson <ron(a)shell.core.com> wrote: >On Apr 24, 2:43�pm, BoneLady <srsuppor...(a)gmail.com> wrote: >> On Apr 23, 6:12�pm, Ron Peterson <r...(a)shell.core.com> wrote: > >> > I don't believe that strontium is considered a nutrient and that makes >> > it difficult to recommend. > >> Strontium is considered to be an essential nutrient like calcium and >> is available in small amounts from food. It is believed that the >> strontium-calcium bone matrix is far stronger than calcium matrix >> alone. > >Who considers strontium to be an essential nutrient? > >Is there a study that indicates that strontium in the bone matrix is >the cause of higher bone strength? The physician's information sheet packed with the Strontium Renelate I am taking includes some details of the studies made: Two placebo controlled phase III studies: SOTI and TROPOS study. SOTI involved 1,649 postmenopausal women with established osteoporosis (low lumber BMD and prevalent vertebral fracture) and a mean age of 70 years....1,556 patients over 80 years at inclusion...reduced the relative risk of fracture by 41 % over 3 years in the SOTI study (table 1)... Bruce-in-Bangkok (correct Address is bpaige125atgmaildotcom)
From: trigonometry1972 on 1 May 2008 03:18 Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. Seeman E, Devogelaer JP, Lorenc R, Spector T, Brixen K, Balogh A, Stucki G, Reginster JY. Austin Health, University of Melbourne, Australia. egos(a)unimelb.edu.au Many fractures occur in women with moderate fracture risk caused by osteopenia. Strontium ranelate was studied in 1431 postmenopausal women with osteopenia. Vertebral fracture risk reduction of 41-59% was shown depending on the site and fracture status at baseline. This is the first report of antivertebral fracture efficacy in women with vertebral osteopenia. INTRODUCTION: Women with osteoporosis are at high risk for fracture. However, more than one half of all fractures in the community originate from the larger population at more moderate risk of fracture caused by osteopenia. Despite this, evidence for antifracture efficacy in these persons is limited. The aim of this study was to determine whether strontium ranelate, a new drug that reduces fracture risk in women with o steoporosis, is also effective in women with osteopenia. MATERIALS AND METHODS: Data from the Spinal Osteoporosis Therapeutic Intervention study (SOTI; n = 1649) and the TReatment Of Peripheral OSteoporosis (TROPOS; n = 5091) were pooled to evaluate the antivertebral fracture efficacy of strontium ranelate in women with lumbar spine (LS) osteopenia with any BMD value at the femoral neck (FN; N = 1166) and in 265 women with osteopenia at both sites (intention-to-treat analysis). The women were randomized to strontium ranelate 2 g/d orally or placebo for 3 yr. RESULTS: No group differences were present in baseline characteristics that may influence fracture outcome independent of therapy. In women with LS osteopenia, treatment reduced the risk of vertebral fracture by 41% (RR = 0.59; 95% CI, 0.43-0.82), by 59% (RR = 0.41; 95% CI, 0.17-0.99) in the 447 patients with no prevalent fractures, and by 38% (RR = 0.62; 95% CI, 0.44-0.88) in the 719 patients with prevalent fractures. In women with osteopenia at both sites, treatment reduced the risk of fracture by 52% (RR = 0.48; 95% CI, 0.24-0.96). CONCLUSIONS: Strontium ranelate safely reduces the risk of vertebral fractures in women with osteopenia with or without a prevalent fracture. PMID: 17997711
From: trigonometry1972 on 1 May 2008 03:18 Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. Seeman E, Devogelaer JP, Lorenc R, Spector T, Brixen K, Balogh A, Stucki G, Reginster JY. Austin Health, University of Melbourne, Australia. egos(a)unimelb.edu.au Many fractures occur in women with moderate fracture risk caused by osteopenia. Strontium ranelate was studied in 1431 postmenopausal women with osteopenia. Vertebral fracture risk reduction of 41-59% was shown depending on the site and fracture status at baseline. This is the first report of antivertebral fracture efficacy in women with vertebral osteopenia. INTRODUCTION: Women with osteoporosis are at high risk for fracture. However, more than one half of all fractures in the community originate from the larger population at more moderate risk of fracture caused by osteopenia. Despite this, evidence for antifracture efficacy in these persons is limited. The aim of this study was to determine whether strontium ranelate, a new drug that reduces fracture risk in women with o steoporosis, is also effective in women with osteopenia. MATERIALS AND METHODS: Data from the Spinal Osteoporosis Therapeutic Intervention study (SOTI; n = 1649) and the TReatment Of Peripheral OSteoporosis (TROPOS; n = 5091) were pooled to evaluate the antivertebral fracture efficacy of strontium ranelate in women with lumbar spine (LS) osteopenia with any BMD value at the femoral neck (FN; N = 1166) and in 265 women with osteopenia at both sites (intention-to-treat analysis). The women were randomized to strontium ranelate 2 g/d orally or placebo for 3 yr. RESULTS: No group differences were present in baseline characteristics that may influence fracture outcome independent of therapy. In women with LS osteopenia, treatment reduced the risk of vertebral fracture by 41% (RR = 0.59; 95% CI, 0.43-0.82), by 59% (RR = 0.41; 95% CI, 0.17-0.99) in the 447 patients with no prevalent fractures, and by 38% (RR = 0.62; 95% CI, 0.44-0.88) in the 719 patients with prevalent fractures. In women with osteopenia at both sites, treatment reduced the risk of fracture by 52% (RR = 0.48; 95% CI, 0.24-0.96). CONCLUSIONS: Strontium ranelate safely reduces the risk of vertebral fractures in women with osteopenia with or without a prevalent fracture. PMID: 17997711
|
Next
|
Last
Pages: 1 2 3 Prev: Vitamin D lecture Next: Could Strontium Citrate Contain Strontium-90? |